Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Apr 14 2026 | April Issue of Journal of Cardiac Failure Highlights Include High Mortality in Cardiogenic Shock Driven by Valvular Heart Disease; Potential Dementia Risk Reduction with SGLT2 Inhibitors HFSA News Journal of Cardiac Failure Press Release Read More Apr 7 2026 | HFSA Awards: Nominations Now Open through May 3, 2026 HFSA News Awards Read More Apr 7 2026 | Welcoming March's New HFSA Members HFSA News Membership Read More Apr 5 2026 | HFSA President's Update: April 2026 HFSA News President's Updates Read More Apr 1 2026 | FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Industry News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Apr 14 2026 | April Issue of Journal of Cardiac Failure Highlights Include High Mortality in Cardiogenic Shock Driven by Valvular Heart Disease; Potential Dementia Risk Reduction with SGLT2 Inhibitors HFSA News Journal of Cardiac Failure Press Release Read More
Apr 1 2026 | FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Industry News Industry Read More
